Clinical trial VERT-002
A First-In-Human (FIH) phase I/II open-label, multicenter, dose escalation and expansion trial of VERT-002 in patients with locally advanced or metastatic solid tumors including non-small cell lung cancer (NSCLC) harboring MET alterations (F60089IV101)
| Cancers | |
|---|---|
| Organ | Lung |
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 1/2 |
| Academic trial | Non |
| Sponsor | Pierre Fabre |
| EudraCT Identifier | 2024-512760-64-00 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT06669117 |
| Last update |